Montelukast

• Antiarrhythmic Agents
• ATC:R03DC03

• Singulair
• Singular

No information avaliable

C₃₅H₃₆ClNO₃S

http://www.rxlist.com/cgi/generic3/monteluk.htm

Montelukast FDA

ML Belley et al., Eur. Pat. Appl. 480,717 (1992)

586.184 g/mol

No information avaliable

No hay información disponible

Solid

8.488

Tablet (oral)

Para el tratamiento del asma

Montelukast, zafirlukast como, es un antagonista del receptor de leucotrienos utilizado como una alternativa a los medicamentos anti-inflamatorios en la gestión y el tratamiento crónico del asma y broncoespasmo inducido por el ejercicio (BEI). A diferencia de zafirlukast, montelukast no inhibe CYP2C9 o CYP3A4 y, por tanto, no espera que afecte a la eliminación hepática de los fármacos metabolizados por estas enzimas.

Absorbe rápidamente tras la administración oral (biodisponibilidad es del 64%)

Los efectos secundarios incluyen dolor de cabeza, dolor abdominal o estomacal, tos, dolor dental, mareos, fiebre, ardor de estómago, erupciones en la piel, congestión nasal, debilidad o cansancio inusual.

General

• Patients should be advised to take montelukast daily as prescribed, even when they are asymptomatic, as well as during periods of worsening asthma, and to contact their physicians if their asthma is not well controlled.
• Patients should be advised that oral tablets of montelukast are not for the treatment of acute asthma attacks. They should have appropriate short-acting inhaled b-agonist medication available to treat asthma exacerbations.
• Patients should be advised that, while using montelukast, medical attention should be sought if short-acting inhaled bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for 24-hour period are needed.
• Patients receiving montelukast should be instructed not to decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
• Patients who have exacerbations of asthma after exercise should be instructed to continue to use their usual regimen of inhaled b-agonists as prophylaxis unless otherwise instructed by their physician. All patients should have available for rescue a short-acting inhaled b-agonist.
• Patients with known aspirin sensitivity should be advised to continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast.

Chewable Tablets:

Phenylketonurics: Phenylketonuric patients should be informed that the chewable tablet contains phenylalanine (a component of aspartame) 0.842 mg per 5-mg chewable tablet.

Humanos y otros mamíferos